In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto’s Munk School of Global Affairs, writes that, “for the second year in a row, the amount of attention devoted to global health” at the annual G8 summit, which took place at Camp David in Maryland in May, has declined. “Global health was not completely absent from the summit,” she continues, highlighting several health initiatives discussed at the meeting, including the New Alliance for Food Security and Nutrition, launched “to accelerate the flow of private capital to African agriculture” with an aim of “lift[ing] 50 million people out of poverty over the next decade.”
“Researchers who tested a novel type of antibiotic against multi-drug-resistant tuberculosis [MDR-TB] are reporting that nearly half of patients who got the new drug cleared the bacteria from their lung fluid in two months,” according to a study published Thursday in the New England Journal of Medicine, Reuters reports. Japanese pharmaceutical company Otsuka developed the experimental drug, delamanid, and “also designed and financed the clinical trial, which took place in 17 medical centers across nine countries,” the news service writes (Emery, 6/6).
During a live webcast discussing recent changes at the Global Fund to Fight AIDS, Tuberculosis and Malaria, “[p]anelists discussed the fund’s new strategy and what this strategy means for the global fight against these three diseases,” GlobalPost’s “Global Pulse” blog reports. J. Stephen Morrison, senior vice president and director of the Global Health Policy Center at the Center for Strategic and International Studies, noted the Global Fund’s new general manager, Gabriel Jaramillo, had moved quickly in focusing on restructuring and realigning the fund, according to the blog. Todd Summers, independent consultant and chair of the Strategy, Investment & Impact Committee at the Global Fund, said, “Now we see lots of opportunity to really make a big difference and change forever the trajectory” of the epidemics, “Global Pulse” notes.
The Wall Street Journal reports on a rise of multi-drug resistant tuberculosis (TB) in India, writing, “India’s slow response to years of medical warnings now threatens to turn the country into an incubator for a mutant strain of tuberculosis that is proving resistant to all known treatments, raising alarms of a new global health hazard.” The newspaper continues, “Spread of the strain could return tuberculosis to the fatal plague that killed two-thirds of people afflicted, before modern treatments were developed in the 1940s, said Dr. Mario Raviglione, director of the Stop TB Department of the World Health Organization.” The newspaper notes, “The WHO is now assisting India to combat the strain” (Anand, 6/19).
In this NDTV opinion piece, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, reflects on his recent trip to India, writing, “During my recent visit, I had a chance to see the latest progress on things that matter a lot to us: on eradicating polio and curtailing the spread of infectious diseases like HIV/AIDS and tuberculosis, for example.” He continues, “And I saw how India is emerging as a model and increasingly a catalyst for improvement in other developing countries,” adding, “The current situation in India is quite hopeful.”
In a study published on Wednesday in the Lancet, researchers from the Centers for Disease Control and Prevention found that “[a]mong 1,278 patients who were resistant to two or more first-line tuberculosis drugs in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea and Thailand, 43.7 percent showed resistance to at least one second-line drug,” which “suggest[s] the deadly disease may become ‘virtually untreatable,’” according to the study, Bloomberg Businessweek reports (Kitamura/Narayan, 8/29). “In about a fifth of cases, they found resistance to at least one second-line injectable [versus oral] drug,” according to Reuters, which states “[t]his ranged from two percent in the Philippines to 47 percent in Latvia.” Overall, 6.7 percent of patients had extensively drug-resistant TB (XDR-TB), meaning patients are resistant to the first-line drugs isoniazid and rifampicin as well as drugs in the fluoroquinolone antibiotic class and a second-line injectable antibiotic, Reuters adds, noting “[r]ates in South Korea, at 15.2 percent, and Russia at 11.3 percent, were more than twice the WHO’s global estimate of 5.4 percent at that time” (Kelland, 8/30).
The Washington Post examines how the “discovery of an almost untreatable form of tuberculosis [TB] in India has set off alarm bells around the world and helped spur a dramatic expansion of government efforts to battle the killer lung disease.” The newspaper writes, “For the past decade, a nationwide tuberculosis program involving millions of health workers and volunteers has made slow but significant progress in battling the disease in India and has been hailed as a public health success story,” but “any sense of complacency was dispelled in December when a doctor in Mumbai, Zarir Udwadia, discovered a strain of the disease that did not respond to any of the 12 frontline drugs.”
French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance “to accelerate the discovery and development of novel compounds against tuberculosis,” RTTNews reports (9/20). “According to company material, the projects will explore a compound which researchers believe has potential to treat all forms of tuberculosis, investigate another class of natural derivatives that has shown ‘impressive’ activity against tuberculosis bacteria, and identify future candidates for development among chemical compounds in Sanofi’s collection,” the Center for Global Health Policy’s “Science Speaks” blog writes (Barton, 9/20). RTTNews notes, “Sanofi, which discovered rifampicin in the early 1960s, markets several anti-tuberculosis drugs” (9/20).
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria’s Transitional Funding Mechanism (TFM), stating, “Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM.” The news service notes, “Almost 25 percent of this combined total will go towards [tuberculosis (TB)], which represents a significant increase from the average 16 percent of funds allocated for TB since the Global Fund was created in 2002, according to a StopTB Partnership statement released in response” to the fund’s announcement. PlusNews notes, “Unlike regular grants, which can run for up to five years, those awarded under the TFM will be limited to two years, by which time the fund is expected to have launched its new funding model” (9/4).
Secretary of State Hillary Clinton reflects on changes in U.S. global health diplomacy since taking office in this Global Health and Diplomacy opinion piece. “America had been leading the global health fight for decades,” but “we recognized that to sustain the impact of our work, we needed to change the way we did business,” she writes. “For example, while our agencies were providing tremendous leadership in isolation, they could still do more to collaborate effectively,” she writes, adding, “[W]e weren’t doing enough to coordinate our efforts with other donors or our partner countries,” and “we weren’t building sustainable systems to eventually allow our partner countries to manage more of their own health needs.” She says, “We were unintentionally putting a ceiling on the number of lives we could save.”